Published in Am J Epidemiol on May 01, 1994
The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health (2002) 8.17
Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health (2004) 3.32
Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health (2004) 2.27
Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection. J Urban Health (2005) 1.54
HIV and AIDS surveillance among inmates in Maryland prisons. J Urban Health (2001) 1.52
Cost-effectiveness of HIV counseling and testing in US prisons. J Urban Health (2001) 1.39
Disease prevalence and use of health care among a national sample of black and white male state prisoners. J Health Care Poor Underserved (2012) 1.34
From corrections to communities as an HIV priority. J Urban Health (2006) 1.22
Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol (1999) 1.15
Characteristics and trends of newly identified HIV infections among incarcerated populations: CDC HIV voluntary counseling, testing, and referral system, 1992-1998. J Urban Health (2001) 1.15
The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis. Am J Public Health (2015) 1.11
HIV and hepatitis C virus testing and seropositivity rates in Canadian federal penitentiaries: A critical opportunity for care and prevention. Can J Infect Dis Med Microbiol (2004) 1.09
HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. Curr Opin Infect Dis (2013) 1.07
An evaluation of HIV testing among inmates in the North Carolina prison system. Am J Public Health (2009) 1.05
Implementing a routine, voluntary HIV testing program in a Massachusetts county prison. J Urban Health (2006) 0.99
Increasing voluntary HIV testing by offering oral tests in incarcerated populations. Am J Public Health (2001) 0.98
Health care in correctional facilities. West J Med (1995) 0.98
Young incarcerated men's perceptions of and experiences with HIV testing. Am J Public Health (2007) 0.97
Establishment of an HIV/sexually transmitted disease programme and prevalence of infection among incarcerated men in Jamaica. Int J STD AIDS (2010) 0.86
Opt-out HIV testing in prison: informed and voluntary? AIDS Care (2014) 0.84
High HIV prevalence and associated factors in a remote community in the Rwenzori region of Western Uganda. Infect Dis Rep (2010) 0.83
Using arrest charge to screen for undiagnosed HIV infection among new arrestees: a study in Los Angeles County. J Correct Health Care (2009) 0.82
HIV coping self-efficacy: a key to understanding stigma and HIV test acceptance among incarcerated men in Jamaica. AIDS Care (2010) 0.80
Factors Associated with Recent HIV Testing among Heterosexuals at High Risk for HIV Infection in New York City. Front Public Health (2016) 0.79
Routine testing for blood-borne viruses in prisons: a systematic review. Eur J Public Health (2015) 0.78
Profile of HIV seropositive inmates diagnosed in Maryland's state correctional system. Public Health Rep (1995) 0.75
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health (1996) 5.45
Sex differences in HIV-1 viral load and progression to AIDS. Lancet (1998) 5.24
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
Self-reported antiretroviral therapy in injection drug users. JAMA (1998) 4.75
Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. Arch Intern Med (2001) 4.68
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA (1992) 3.81
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.68
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS (2001) 3.56
Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA (1998) 3.07
Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA (1992) 3.07
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Factors associated with adolescent initiation of injection drug use. Public Health Rep (2001) 2.73
Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med (2001) 2.68
Correlates of HIV infection among young adult short-term injection drug users. AIDS (2000) 2.63
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol (1997) 2.55
Using social network analysis to study patterns of drug use among urban drug users at high risk for HIV/AIDS. Drug Alcohol Depend (1995) 2.51
Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol (1997) 2.48
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol (1997) 2.32
Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants. Am J Epidemiol (2003) 2.32
People and places: behavioral settings and personal network characteristics as correlates of needle sharing. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.26
Vitamin A deficiency and wasting as predictors of mortality in human immunodeficiency virus-infected injection drug users. J Infect Dis (1995) 2.25
Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A (2000) 2.24
Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health (2001) 2.21
Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md. Arch Intern Med (1995) 2.08
Explaining racial disparities in incidence of and survival from out-of-hospital cardiac arrest. Am J Epidemiol (2007) 2.07
The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: the SAFE Study. Am J Community Psychol (1996) 2.07
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction (1993) 2.01
Transmission of HIV-1 within a statewide prison system. AIDS (1988) 2.00
Occupational risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infections among funeral service practitioners in Maryland. Infect Control Hosp Epidemiol (1995) 1.95
Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev (1994) 1.87
Compliance with universal precautions among health care workers at three regional hospitals. Am J Infect Control (1995) 1.83
Gender differences in the initiation of injection drug use among young adults. J Urban Health (2000) 1.78
Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol (1991) 1.76
Discarded needles do not increase soon after the opening of a needle exchange program. Am J Epidemiol (1997) 1.76
Syphilis serology in human immunodeficiency virus infection: evidence for false-negative fluorescent treponemal testing. J Infect Dis (1997) 1.74
Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol (1993) 1.73
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A (1998) 1.72
Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health (1999) 1.71
My place, your place, and no place: behavior settings as a risk factor for HIV-related injection practices of drug users in Baltimore, Maryland. Am J Community Psychol (1994) 1.71
Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS (2000) 1.70
Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women. HIV Epidemiology Research Study Group. Clin Infect Dis (1999) 1.69
Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. Am J Public Health (1991) 1.68
HIV risk behaviors and their relationship to posttraumatic stress disorder among women prisoners. Psychiatr Serv (2001) 1.67
Risk factors for shooting gallery use and cessation among intravenous drug users. Am J Public Health (1991) 1.66
Collaboration among community members, local health service providers, and researchers in an urban research center in Harlem, New York. Public Health Rep (2002) 1.65
Seroepidemiology of hepatitis B virus in a population of injecting drug users. Association with drug injection patterns. Am J Epidemiol (1995) 1.65
The relationship between risk networks' patterns of crack cocaine and alcohol consumption and HIV-related sexual behaviors among adult injection drug users: a prospective study. Drug Alcohol Depend (1996) 1.59
Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection. Am J Epidemiol (1993) 1.59
Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med (1996) 1.59
Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island. J Acquir Immune Defic Syndr (1999) 1.57
Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol (2000) 1.57
Access to medical care and service utilization among injection drug users with HIV/AIDS. Drug Alcohol Depend (2001) 1.57
Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J Infect Dis (1997) 1.54
Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis (1996) 1.53
Measurement of HIV risk behaviors among intravenous drug users. Br J Addict (1992) 1.53
Selective risk taking among needle exchange participants: implications for supplemental interventions. Am J Public Health (2001) 1.52
New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. Am J Epidemiol (1991) 1.52
The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am J Public Health (1994) 1.52
Can HIV epidemics among injection drug users be prevented? AIDS (1998) 1.51
An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis (1996) 1.51
Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis (1999) 1.51
Differences in risk factors for human immunodeficiency virus type 1 seroconversion among male and female intravenous drug users. Am J Epidemiol (1993) 1.51
Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis (1999) 1.48
Needle-exchange attendance and health care utilization promote entry into detoxification. J Urban Health (1999) 1.47
Suspected determinants of enrollment into detoxification and methadone maintenance treatment among injecting drug users. Drug Alcohol Depend (1994) 1.47
Modification of syphilitic genital ulcer manifestations by coexistent HIV infection. Sex Transm Dis (2001) 1.47
Opiates as potential cofactors in progression of HIV-1 infections to AIDS. J Neuroimmunol (1998) 1.46
Criteria for assessing cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiologic Research Study Group. J Allergy Clin Immunol (1999) 1.46
Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users. J Acquir Immune Defic Syndr (1992) 1.45
Drug abuse treatment success among needle exchange participants. Public Health Rep (1998) 1.45
Update on the seroepidemiology of human immunodeficiency virus in the United States household population: NHANES III, 1988-1994. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.44
Gender differences in injection-related behaviors among injection drug users in Baltimore, Maryland. AIDS Educ Prev (1998) 1.43
Human immunodeficiency virus infection in diabetic intravenous drug users. JAMA (1991) 1.39
Increased mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 infection. Arch Intern Med (1993) 1.39
Comment on TMD. Am J Orthod Dentofacial Orthop (1995) 1.38
Sexually transmitted diseases in a population of intravenous drug users: association with seropositivity to the human immunodeficiency virus (HIV). J Infect Dis (1991) 1.37
Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.37
The effect of a needle exchange program on numbers of discarded needles: a 2-year follow-up. Am J Public Health (2000) 1.36
Determinants of the quantity of hepatitis C virus RNA. J Infect Dis (2000) 1.32
Injecting misuse of buprenorphine among French drug users. Addiction (2001) 1.31
Differences in the incidence of hepatitis B and human immunodeficiency virus infections among injecting drug users. J Infect Dis (1996) 1.30
The prevalence of homelessness among injection drug users with and without HIV infection. J Urban Health (2000) 1.30
Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res (1999) 1.30
Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons. Clin Infect Dis (1997) 1.29
Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J Med Virol (1989) 1.27
The urban built environment and overdose mortality in New York City neighborhoods. Health Place (2005) 1.27
The urban health "advantage". J Urban Health (2005) 1.25
Antibodies to Bartonella species in inner-city intravenous drug users in Baltimore, Md. Arch Intern Med (1996) 1.24